Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients

Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients

<i>Pexa-Vec</i> is an engineered Wyeth-strain vaccinia oncolytic virus (OV), which has been tested extensively in clinical trials, demonstrating enhanced cytotoxic T cell infiltration into tumours following treatment. Favourable immune consequences to <i>Pexa-Vec</i> include...

Full description

Bibliographic Details
Main Authors: Emma J. West, Karen J. Scott, Emma Tidswell, Kaidre Bendjama, Nicolas Stojkowitz, Monika Lusky, Marta Kurzawa, Raj Prasad, Giles Toogood, Christy Ralph, D. Alan Anthoney, Alan A. Melcher, Fiona J. Collinson, Adel Samson
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
vaccinia virus
oncolytic virus therapy
immunotherapy
biomarkers
interferon response
immune checkpoint blockade
Online Access:https://www.mdpi.com/2072-6694/14/9/2181

Internet

https://www.mdpi.com/2072-6694/14/9/2181

Similar Items